Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

RWC Update: Modern One Health Approaches to Novel Challenges in Infectious Uveitis-Parasitic, Fungal and Mycobacterial Uveitis (Part 2); Management of 180° Iridodialysis With Aphakia and Total Hyphema; Retinal Astrocytic Hamartoma.

Ophthalmic surgery, lasers & imaging retina·2026

Same author

Rethinking phase III trials in retinal biosimilars: Do we still need them?

Eye (London, England)·2026

Same author

RWC Update: Modern One Health Approaches to Novel Challenges in Infectious Uveitis-Emerging Viral Diseases (Part 1); Repair of Closed Funnel Retinal Detachment Through Boston KPro; Choroidal Rupture.

Ophthalmic surgery, lasers & imaging retina·2026

Same author

Anti-Vascular Endothelial Growth Factor Biosimilars for Use in the Aging Eye.

Drugs & aging·2026

Same author

Retinal progenitor cells (jCell) for retinitis pigmentosa.

Frontiers in cellular neuroscience·2025

Same author

Secondary Macular Hole Closure With Sub-Tenon Triamcinolone Acetonide.

Journal of vitreoretinal diseases·2025

Search research articles

Related Experiment Video

Updated: May 19, 2026

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

Ocriplasmin for pharmacologic vitreolysis.

Baruch D Kuppermann¹

¹Retina Service at the Gavin Herbert Eye Institute, Department of Ophthalmology, University of California, Irvine, CA, USA. bdkupper@uci.edu

Retina (Philadelphia, Pa.)

|August 30, 2012

Summary

Pharmacologic vitreolysis, using ocriplasmin, offers a nonsurgical treatment for vitreomacular adhesion and macular holes. This advancement provides an effective alternative for managing these retinal disorders.

More Related Videos

Intravitreal Injections in the Ovine Eye

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

Intracameral Injection in Rats with Low Risk of Adverse Effects

Intracameral Injection in Rats with Low Risk of Adverse Effects

Published on: May 31, 2024

Related Experiment Videos

Last Updated: May 19, 2026

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

Intravitreal Injections in the Ovine Eye

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

Intracameral Injection in Rats with Low Risk of Adverse Effects

Intracameral Injection in Rats with Low Risk of Adverse Effects

Published on: May 31, 2024

Area of Science:

Ophthalmology
Retinal Disorders
Pharmacology

Background:

The vitreous humor is implicated in the pathogenesis of several retinal disorders.
Pharmacologic vitreolysis aims to liquefy the vitreous and achieve vitreoretinal separation.

Purpose of the Study:

To summarize recent advancements in pharmacologic vitreolysis.
To discuss the efficacy and safety of ocriplasmin for retinal conditions.

Main Methods:

A roundtable discussion among clinical investigators.
Presentation and discussion of preclinical data.
Review of efficacy and safety data from controlled clinical trials of ocriplasmin.
Presentation of case studies.

Main Results:

Ocriplasmin has demonstrated the ability to safely release vitreomacular adhesion.
Ocriplasmin has shown success in closing Stage 2 macular holes in a significant number of patients.
Clinical data supports ocriplasmin as a safe and effective treatment option.

Conclusions:

Pharmacologic vitreolysis with ocriplasmin presents a viable nonsurgical treatment alternative.
Ocriplasmin is effective for treating vitreomacular adhesion, vitreomacular traction, and macular holes.
Expert interpretation of clinical data and experience supports ocriplasmin's use.